Physician profile
Zoe Veritas
NPI 1881741544
$9,605.39
in general payments reported to CMS, 2019-2025
36 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $710 · 2021: $2,079 · 2022: $1,032 · 2023: $1,509 · 2024: $1,583 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.45 |
| Education | $339.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.16 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $930.52 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $804.03 | 2022-2025 | Sotyktu |
| Amgen INC. | $663.69 | 2020-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $650.30 | 2019-2025 | Dupixent, Libtayo |
| Senseonics, Incorporated | $640.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $630.59 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $448.25 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $441.78 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $328.50 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $315.47 | 2019-2025 | |
| Ucb, INC. | $299.13 | 2019-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $266.76 | 2019-2023 | |
| Celgene Corporation | $260.11 | 2019 | |
| Mayne Pharma Commercial LLC | $219.46 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $190.11 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $172.51 | 2019-2021 | |
| Epi Health, LLC | $161.70 | 2019-2022 | |
| Biofrontera INC. | $150.24 | 2020-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $117.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.55 | 2020-2024 | |
| Incyte Corporation | $113.48 | 2021-2025 | Opzelura, Opzelura |
| Strata Skin Sciences, INC. | $96.90 | 2019-2025 | Xtrac |
| Almirall LLC | $65.13 | 2019-2021 | |
| Journey Medical Corporation | $65.10 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $53.89 | 2020-2021 | |
| Taro Pharmaceuticals USA, INC. | $41.70 | 2019 | |
| Sebela Pharmaceuticals INC. | $39.40 | 2021-2023 | Naftin, Pramosone |
| Kyowa Kirin, INC. | $37.46 | 2022-2023 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $36.06 | 2019 | |
| Lnhc, INC | $35.57 | 2025 | Zelsuvmi |
| Ascensia Diabetes Care US INC. | $30.08 | 2021 | |
| Allergan, INC. | $24.12 | 2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $18.79 | 2019 | |
| Aclaris Therapeutics, INC. | $17.62 | 2019 | |
| Botanix Sb INC | $16.07 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Veritas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.